Novo Nordisk considers upgrading its US listing, FT reports

Novo Nordisk is considering upgrading its US listing, the Financial Times reports. The drugmaker's shares currently trade in Copenhagen and as ADRs in New York.

Detected & updated continuously · Source: Nebula